Skip to content
montabiosciences.commontabiosciences.com
  • Home
  • About us
    • Company History
    • Management
    • Board of Directors
    • Founders
  • Technology
    • Todays Challenges
    • Cancer Treatment
    • Cancer Immunotherapy
    • Development
    • References
  • News
  • Contact Us
The AngloNordic Life science conference
May 10, 2018

MonTa Biosciences attend the AngloNordic Life science conference in London on Mya 24th to meet investors and network [...]

Attending the Biotechandmoney conference
January 5, 2018

MonTa Biosciences attend the Biotechandmoney conference in London on February 5-6. [...]

BioEurope partnering conference in Berlin
November 5, 2017

MonTa Biosciences attends the BioEurope partnering conference in Berlin from November 4-8. Please book a meeting with [...]

Completion of license agreements
October 5, 2017

MonTa Biosciences announces completion of license agreements with UC San Diego and Danish Technical University. The immune [...]

Nordic Life Science Days in Malmö
September 5, 2017

MonTa Biosciences attends the Nordic Life Science Days in Malmö to meet with investors and pharma partners. [...]

Esper Boel joins Board of Directors
April 5, 2017

MonTa Biosciences recruits PhD, Esper Boel former SVP in Novo Nordisk and strategic adviosor in immunotherapy to its Board [...]

BioEurope Spring in Barcelona
March 5, 2017

MonTa Biosciences attends BioEurope Spring in Barcelona to have meetings with more than 10 of the top [...]

Investment from Pre-Seed Innovation
March 5, 2017

MonTa Biosciences closes an investment from Pre-Seed Innovation to reach key milestones for our cancer [...]

Joining the NOME Mentoring programme
September 5, 2016

MonTa Biosciences join the NOME Mentoring programme in the North Carolina Research Triangle and are appointed top [...]

MonTa Biosciences included in the NOME Nordic Mentoring Network for Entrepreneurship
August 5, 2016

MonTa Biosciences awarded to be included in the NOME Nordic Mentoring Network for Entrepreneurship. MonTa Biosciences is priviledged to be part [...]

Article published by the Danish Biotech media, Medwatch
May 5, 2016

A news article was published by the Danish Biotech media; Medwatch on the newly granted [...]

Granted an Investment from “Innovationsfonden”
April 5, 2016

MonTa Biosciences is part of the XVac “Grand Solutions”  granted an Investment from “Innovationsfonden”. The XVac project [...]

Co-founder Thomas L Andresen talks in Danish national radio
April 5, 2016

MonTa Biosciences Co-founder Thomas L Andresen talks in Danish national radio about the cancer immunotehrapy [...]

MedWatch publishes article
April 5, 2015

MedWatch publishes article on MonTa Biosciences. [...]

Monocyte targeting technology published
March 5, 2015

The monocyte targeting technology was published in an article in  “Expert Opinion in Drug Delivery”. [...]

Awarded a “Proof-of-Concept” grant from Copenhagen Spin-puts
September 5, 2014

MonTa Biosciences was awarded a “Proof-of-Concept” grant from Copenhagen Spin-puts” to support the early development [...]

Article published in Medwatch
April 5, 2014

An article about MonTa Biosciences was published in Medwatch on April 8, 2014. [...]

Technology presented at the “SITC” in Washington DC
November 5, 2013

The MonTa Biosciences’ technology was presented at the Society for Immunotherapy of Cancer “SITC” in National harbour, [...]

  • 1
  • 2

MonTa Biosciences ApS

Diplomvej 381
2800 Kgs. Lyngby
Denmark

VAT nr. 36697016

    Privacy statement
    MonTa Biosciences - Cancer Therapeutics of Tomorrow
    • Home
    • About us
      • Company History
      • Management
      • Board of Directors
      • Founders
    • Technology
      • Todays Challenges
      • Cancer Treatment
      • Cancer Immunotherapy
      • Development
      • References
    • News
    • Contact Us